Amilasa y lipasa como predictores tempranos de pancreatitis aguda post-colangiografía pancreática retrógrada endoscópica

La Colangiopancreatografía Retrograda Endoscópica (CPRE) es un método invasivo para el tratamiento de las afecciones de la vía biliar. Puede ser muy beneficiosa pero con serias complicaciones, siendo la pancreatitis aguda post-CPRE (PAP) la más frecuente. Predecirla tiene implicancias clínicas y legales. Los aumentos asintomáticos de enzimas pancreáticas luego de una CPRE son comunes hasta el 70% de los casos. En cambio, la PAP se estima en alrededor del 2 al 8% en distintas publicaciones. Una revisión sistemática de 21 estudios prospectivos que incluyen 16.855 pacientes, informa una incidencia de PAP del 3,5% de las cuales un 11% son PAP severas con una mortalidad del 3%. Debido a que en muchas instituciones la CPRE se lleva a cabo en pacientes ambulatorios, el reconocimiento temprano de pacientes con predictores altos para PAP sería el ideal para un enfoque terapéutico temprano y por otro lado para evitar una hospitalización innecesaria. En un estudio realizado en el hospital El Cruce sobre un total de 734 CPRE efectuadas en un período de dos años, se registraron quince PAP (2% de las CPRE realizadas). Una internación por “prevención” sin un correcto diagnóstico, incrementa los costos en salud y la innecesaria utilización de recursos. Por otra parte, el subdiagnóstico y eventual alta ante un caso aún no expreso de PAP impide el tratamiento oportuno con aumento de la morbimortalidad. El objetivo de este trabajo fue determinar si elevaciones por encima de tres veces del valor de referencia de amilasa y lipasa a las dos y cuatro horas posteriores a la CPRE pueden predecir pancreatitis.Facultad de Ciencias Médica

Amilasa y lipasa como predictores tempranos de pancreatitis aguda post-colangiografía pancreática retrógrada endoscópica

La Colangiopancreatografía Retrograda Endoscópica (CPRE) es un método invasivo para el tratamiento de las afecciones de la vía biliar. Puede ser muy beneficiosa pero con serias complicaciones, siendo la pancreatitis aguda post-CPRE (PAP) la más frecuente. Predecirla tiene implicancias clínicas y legales. Los aumentos asintomáticos de enzimas pancreáticas luego de una CPRE son comunes hasta el 70% de los casos. En cambio, la PAP se estima en alrededor del 2 al 8% en distintas publicaciones. Una revisión sistemática de 21 estudios prospectivos que incluyen 16.855 pacientes, informa una incidencia de PAP del 3,5% de las cuales un 11% son PAP severas con una mortalidad del 3%. Debido a que en muchas instituciones la CPRE se lleva a cabo en pacientes ambulatorios, el reconocimiento temprano de pacientes con predictores altos para PAP sería el ideal para un enfoque terapéutico temprano y por otro lado para evitar una hospitalización innecesaria. En un estudio realizado en el hospital El Cruce sobre un total de 734 CPRE efectuadas en un período de dos años, se registraron quince PAP (2% de las CPRE realizadas). Una internación por “prevención” sin un correcto diagnóstico, incrementa los costos en salud y la innecesaria utilización de recursos. Por otra parte, el subdiagnóstico y eventual alta ante un caso aún no expreso de PAP impide el tratamiento oportuno con aumento de la morbimortalidad. El objetivo de este trabajo fue determinar si elevaciones por encima de tres veces del valor de referencia de amilasa y lipasa a las dos y cuatro horas posteriores a la CPRE pueden predecir pancreatitis.Especialista en GastroenterologíaUniversidad Nacional de La PlataFacultad de Ciencias Médica

Pull vs. Wet:Diagnostic performance and sample quality of eus-guided fna in solid lesions of pancreas

Differential diagnosis of pancreatic masses is challenging. The endoscopic ultrasound-guided fine-needle aspiration method with the highest diagnostic yield has not been esta-blished. It was realized a prospective, randomized, double-blind study of the endoscopic ultrasound-guided fine-needle aspiration in solid lesions of the pancreas to compare and evaluate diagnostic yield and aspirate quality between wet and pull technique. Forty-one patients were enrolled. The wet technique presented a sensitivity, a specificity, a positive and negative predictive value, and a diagnostic accuracy of 58.3%, 100%, 100%, 25% and 63.4%, respectively. In the capillary technique they were: 75%, 100%, 100%, 35.7% and 78.1%, respectively. Comparing the diagnostic yield between both techniques, there was no statistically significant difference (McNemar's test p = 0.388). Regarding the cellularity of the specimen, both in cytology and the cell block samples, no significant difference was observed between the techniques (p = 0.84 and 0.61, respectively). With res-pect to contaminating blood in the specimen, there was no difference in cytology samples (p = 0.89) and no difference in cell block samples (p = 0.08). The suitability of cytology samples for diagnosis was similar in both techniques (wet = 57.5% and capillary = 56.7%, p = 0.94) and there was no difference in cell block samples (wet = 75% and capillary = 66.1%, p = 0.38). In this study we did not observe differences in diagnostic yield or sample quality. Since both techniques are effective, we suggest the simultaneous and alternate use of both methods.</p

Nuevos fármacos antiepilépticos en Pediatría

Se estima que unos 70 millones de personas padecen epilepsia a nivel mundial de los cuales más de la mitad son niños, en los que la prevalencia estimada se sitúa en torno al 0,5-0,8%. Aunque existen diversas terapias, el tratamiento de la epilepsia se basa mayoritariamente en fármacos, que en función de su año de comercialización se clasifican como de primera, segunda o tercera generación. En el presente artículo se revisan las principales características de los fármacos antiepilépticos de última generación (lacosamida, acetato de eslicarbazepina, brivaracetam, perampanel, retigabina, everolimus y cannabidiol) que, con excepción de la retigabina (ya no está comercializada), se consideran seguros y efectivos en población pediátrica. El everolimus y el cannabidiol tienen indicaciones muy concretas (esclerosis tuberosa, síndrome de Dravet y síndrome de Lennox Gastaut) mientras que el resto están indicados en el manejo de crisis de origen focal en niños a partir de 4 años. Estas nuevas moléculas han sido desarrolladas para aportar un perfil farmacocinético y de tolerancia superior a los fármacos previamente disponibles y es previsible que a medida que aumente su uso, se vaya perfilando y ampliando su verdadero potencial. Además, por primera vez en epileptología pediátrica, se ha utilizado la extrapolación de datos de efectividad en adultos (junto con estudios de seguridad y farmacocinética específicos en población pediátrica), para acelerar la aprobación de uso en población infantil.It is estimated that about 70 million people all over the world suffer from epilepsy, half of which are children, in whom the prevalence is around 0.5 to 0.8%. Although there are several therapies, the treatment of epilepsy is based mainly on drugs, which, depending on the year of coming onto the market are classified as first, second, or third generation. In this article, a description is presented on the main characteristics of the latest generation of antiepileptic drugs (lacosamide, eslicarbazepine acetate, brivaracetam, perampanel, retigabine, everolimus and cannabidiol). These, with the exception of retigabine (is not yet on the market), are considered safe and effective in the paediatric population. Everolimus and cannabidiol have very specific indications (tuberous sclerosis, Dravet syndrome, and Lennox Gastaut syndrome), while the rest are indicated in the management of seizures of focal origin in children from 4 years-old. These new molecules have been developed in order to provide a pharmaceutical profile and tolerance superior to the previously available drugs, and it is forecast that as their use increases, their true potential and profile will widen. Furthermore, for the first time in Paediatric Epileptology,the extrapolation ofthe efficacy data in adults have been used (together with specific safety and pharmacokinetic studies in the paediatric population), in order to speed up their approval for use in the child population

Herpes simplex virus encephalitis is a trigger of brain autoimmunity

In 5 prospectively diagnosed patients with relapsing post-herpes simplex encephalitis (HSE), N-methyl-D-aspartate receptor (NMDAR) antibodies were identified. Antibody synthesis started 1 to 4 weeks after HSE, preceding the neurological relapse. Three of 5 patients improved postimmunotherapy, 1 spontaneously, and 1 has started to improve. Two additional patients with NMDAR antibodies, 9 with unknown neuronal surface antibodies, and 1 with NMDAR and unknown antibodies, were identified during retrospective assessment of 34 HSE patients; the frequency of autoantibodies increased over time (serum, p=0.004; cerebrospinal fluid, p=0.04). The 3 retrospectively identified NMDAR antibody-positive patients also had evidence of relapsing post-HSE. Overall, these findings indicate that HSE triggers NMDAR antibodies and potentially other brain autoimmunity

Paradigmatic de novo GRIN1 variants recapitulate pathophysiological mechanisms underlying GRIN1-related disorder clinical spectrum

Background: GRIN-related disorders (GRD), the so-called grinpathies, is a group of rare encephalopathies caused by mutations affecting GRIN genes (mostly GRIN1, GRIN2A and GRIN2B genes), which encode for the GluN subunit of the N-methyl D-aspartate (NMDA) type ionotropic glutamate receptors. A growing number of functional studies indicate that GRIN-encoded GluN1 subunit disturbances can be dichotomically classified into gain- and loss-of-function, although intermediate complex scenarios are often present. Methods: In this study, we aimed to delineate the structural and functional alterations of GRIN1 disease-associated variants, and their correlations with clinical symptoms in a Spanish cohort of 15 paediatric encephalopathy patients harbouring these variants. Results: Patients harbouring GRIN1 disease-associated variants have been clinically deeplyphenotyped. Further, using computational and in vitro approaches, we identified different critical checkpoints affecting GluN1 biogenesis (protein stability, subunit assembly and surface trafficking) and/or NMDAR biophysical properties, and their association with GRD clinical symptoms. Conclusions: Our findings show a strong correlation between GRIN1 variants-associated structural and functional outcomes. This structural-functional stratification provides relevant insights of genotypephenotype association, contributing to future precision medicine of GRIN1-related encephalo

Delphi Project on the trends in Implant Dentistry in the COVID-19 era: Perspectives from Latin America

This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.Aim To establish trends in Implant Dentistry in Latin America in the COVID‐19 pandemic. Material and methods A steering committee and an advisory group of experts in Implant Dentistry were selected among eighteen countries. An open‐ended questionnaire by Delphi methodology was validated including 64 questions, divided in 7 topics, concerning the various trends in dental implantology. The survey was conducted in two rounds, which provided the participants in the second round with the results of the first. The questionnaires were completed on August 2020, and the online meeting conference was held on September 2020. The final prediction was developed through consensus by a selected group of experts. Results A total of 197 experts from Latin America answered the first and second questionnaire. In the first round, the established threshold for consensus (65%) was achieved in 30 questions (46.87%). In the second round, performed on average 45 days later, this level was achieved in 47 questions (73.43%). Consensus was completely reached on the item “Diagnostic” (100%), the field with the lowest consensus was “Demand for treatment with dental implants” (37.5%). Conclusions The present study in Latin America has provided relevant and useful information on the predictions in the education and practice of Implant Dentistry in the COVID‐19 era. The consensus points toward a great confidence of clinicians in the biosecurity protocols used to minimize the risk of SARS‐CoV‐2 transmission. It is foreseen as an important change in education, with introduction of virtual reality and other simulation technologies in implant training

Ibero‐Panamerican Federation of Periodontics Delphi study on the trends in diagnosis and treatment of peri‐implant diseases and conditions: A Latin American consensus

Background: The social diversity, heterogeneous culture, and inherent economic inequality factors in Latin America (LA) justify conducting a comprehensive analysis on the current status and future trends of peri-implant diseases and conditions. Thus, the aim of this Delphi study was to predict the future trends in the diagnosis and treatment of peri-implant diseases and conditions in LA countries for the year 2030. Methods: A Latin American steering committee and group of experts in implant dentistry validated a questionnaire including 64 questions divided into eight sections. The questionnaire was run twice with an interval of 45 days, with the results from the first round made available to all the participants in the second round. The results were expressed in percentages and data was analyzed describing the consensus level reached in each question. Results: A total of 221 experts were invited to participate in the study and a total 214 (96.8%) completed the two rounds. Moderate (65%-85%) to high consensus (≥85%) was reached in 51 questions (79.69%), except in the questions dealing with “prevalence”, where no consensus was reached. High and moderate consensus was attained for all the questions in three fields (risk factors and indicators, diagnosis and treatment of peri-implant conditions and deficiencies, and prevention and maintenance). Conclusions: The present study has provided relevant and useful information on the predictions in the diagnosis and treatment of peri-implant diseases with a high level of consensus among experts. Nevertheless, there is still a lack of agreement in certain domains